Lydia Dreosti

6.0k total citations
20 papers, 472 citations indexed

About

Lydia Dreosti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lydia Dreosti has authored 20 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Lydia Dreosti's work include HER2/EGFR in Cancer Research (5 papers), Gastric Cancer Management and Outcomes (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Lydia Dreosti is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Gastric Cancer Management and Outcomes (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Lydia Dreosti collaborates with scholars based in South Africa, United Kingdom and United States. Lydia Dreosti's co-authors include Tetiana Taran, Zhimin Shao, Masakazu Toi, Donggeng Liu, Sara A. Hurvitz, Silvia P. Neciosup, Marc Buyse, Dennis J. Slamon, Zefei Jiang and Qingyuan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Lydia Dreosti

20 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lydia Dreosti South Africa	10	300	179	157	75	73	20	472
Paule Augereau France	11	224 0.7×	133 0.7×	102 0.6×	80 1.1×	24 0.3×	45	402
Georgios Tsakonas Sweden	14	344 1.1×	295 1.6×	145 0.9×	68 0.9×	20 0.3×	48	577
José Manuel Aramendía Spain	14	326 1.1×	275 1.5×	45 0.3×	60 0.8×	46 0.6×	46	587
Craig Vargo United States	8	172 0.6×	102 0.6×	114 0.7×	76 1.0×	37 0.5×	20	340
Sang Hoon Chun South Korea	16	237 0.8×	178 1.0×	193 1.2×	141 1.9×	73 1.0×	54	564
V. Barbounis Greece	15	231 0.8×	115 0.6×	102 0.6×	85 1.1×	18 0.2×	31	481
Pauline du Rusquec France	10	225 0.8×	160 0.9×	93 0.6×	66 0.9×	21 0.3×	25	400
Ratislav Bahleda France	12	218 0.7×	128 0.7×	168 1.1×	114 1.5×	40 0.5×	31	458
Emiddio Barletta Italy	12	395 1.3×	336 1.9×	92 0.6×	82 1.1×	22 0.3×	28	584
Maedeh Barahman Iran	9	106 0.4×	168 0.9×	130 0.8×	67 0.9×	42 0.6×	31	357

Countries citing papers authored by Lydia Dreosti

Since Specialization

Citations

This map shows the geographic impact of Lydia Dreosti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lydia Dreosti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lydia Dreosti more than expected).

Fields of papers citing papers by Lydia Dreosti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lydia Dreosti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lydia Dreosti. The network helps show where Lydia Dreosti may publish in the future.

Co-authorship network of co-authors of Lydia Dreosti

This figure shows the co-authorship network connecting the top 25 collaborators of Lydia Dreosti. A scholar is included among the top collaborators of Lydia Dreosti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lydia Dreosti. Lydia Dreosti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brittain, David, Saad Akhtar, Moosa Patel, et al.. (2024). Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International, Multi-center, Retrospective BHOLISTIC Study. Turkish Journal of Hematology. 41(4). 211–224. 2 indexed citations

Redondo, Andrés, Nicoletta Colombo, Mary McCormack, et al.. (2020). Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecologic Oncology. 159(1). 142–149. 30 indexed citations

Redondo, Andrés, Nicoletta Colombo, Lydia Dreosti, et al.. (2019). Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC). Annals of Oncology. 30. v429–v429. 3 indexed citations

Redondo, Andrés, Nicoletta Colombo, Lydia Dreosti, et al.. (2018). Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC).. Journal of Clinical Oncology. 36(15_suppl). 5528–5528. 5 indexed citations

Reck, Martin, James Chih‐Hsin Yang, Pieter E. Postmus, et al.. (2017). JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC). Annals of Oncology. 28. v492–v492. 5 indexed citations

Sengayi, Mazvita, Danuta Kielkowski, Matthias Egger, Lydia Dreosti, & Julia Bohlius. (2017). Survival of patients with Kaposi’s sarcoma in the South African antiretroviral treatment era: A retrospective cohort study. South African Medical Journal. 107(10). 871–871. 15 indexed citations

Rapoport, Bernardo L., et al.. (2017). Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program. Journal of Global Oncology. 3(5). 515–523. 3 indexed citations

Ghosn, Marwan, et al.. (2017). Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East. 1(2). 5 indexed citations

Johnston, Stephen, Mark Basik, Roberto Hegg, et al.. (2016). Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. Breast Cancer Research and Treatment. 160(1). 91–99. 34 indexed citations

10.

Reck, Martin, Andrea L. Rose, Nick Pavlakis, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. Journal of Clinical Oncology. 34(15_suppl). TPS9105–TPS9105. 9 indexed citations

11.

Hurvitz, Sara A., Fabrice André, Zefei Jiang, et al.. (2015). Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet Oncology. 16(7). 816–829. 231 indexed citations

12.

Zekri, Jamal, et al.. (2015). Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. Journal of Multidisciplinary Healthcare. 8. 335–335. 9 indexed citations

13.

Nemunaitis, John, Robert Hans Ingemar Andtbacka, Merrick I. Ross, et al.. (2014). Results of the Extension Trial of Optim, a Multicenter, Randomized Phase 3 Trial of Talimogene Laherparepvec (T-Vec) Vs Gm-Csf for Unresected Stage Iiib-Iv Melanoma. Annals of Oncology. 25. iv382–iv382. 5 indexed citations

14.

Dreosti, Lydia, et al.. (2014). A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer. Europe PMC (PubMed Central). 2014. 1–8. 3 indexed citations

15.

Azim, Hatem A., Dominique Agbor‐Tarh, Ian Bradbury, et al.. (2013). Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. Journal of Clinical Oncology. 31(36). 4504–4511. 45 indexed citations

16.

Johnston, Stephen, Mark Basik, Roberto Hegg, et al.. (2013). Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).. Journal of Clinical Oncology. 31(15_suppl). 531–531. 17 indexed citations

17.

Louw, Vernon, Lydia Dreosti, Paul Ruff, et al.. (2011). Recommendations for the management of adult chronic myeloid leukaemia in South Africa.. PubMed. 101(11). 840–6. 4 indexed citations

18.

Wardley, Andrew, Caroline Lohrisch, Anil A. Joy, et al.. (2009). Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC).. Cancer Research. 69(2_Supplement). 1035–1035. 5 indexed citations

19.

Dreosti, Lydia, et al.. (1994). Bone Marrow Necrosis Following ALL-Trans Retinoic Acid Therapy for Acute Promyelocytic Leukaemia. Leukemia & lymphoma. 13(3-4). 353–356. 11 indexed citations

20.

Lipman, Jeffrey, Ian Jardine, Carolien Roos, & Lydia Dreosti. (1982). Intravenous calcium chloride as an antidote to verapamil-induced hypotension. Intensive Care Medicine. 8(1). 55–57. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact